Stop screening for inherited thrombophilias in patients with adverse pregnancy outcomes


It's important to understand that most positive associations between inherited thrombophilias and adverse pregnancy outcomes were derived from small case-control studies subject to selection and ascertainment biases.

Case-control studies

Prior case-control studies had implicated thrombophilias in recurrent fetal loss. In 1996, a case-control study nested in the European Prospective Cohort on Thrombophilia (EPCOT) compared 571 women with thrombophilia with 395 control patients and reported an increased risk of fetal loss (miscarriage and stillbirth) among the former patients (29.4% vs 23.5%; P=.04).2 The risk of loss was greater after 28 weeks than at or before 28 weeks (odds ratio [OR], 3.6; 95% confidence interval [CI], 1.4-9.4] vs OR, 1.27; 95% CI, 0.94-1.71). The highest risk for stillbirth was observed in women with combined thrombophilic defects and antithrombin and protein C deficiencies. A 1998 study found a prevalence of FVL in 8.0% of consecutively tested recurrent aborters vs 3.7% of parous controls (OR, 2.3; 95% CI, 1.0-5.2).3 In a meta-analysis of 31 studies, FVL was associated with first-trimester pregnancy loss (OR, 2.01; 95% CI, 1.13-3.58) but more strongly with late (>19 weeks) nonrecurrent fetal loss (OR, 3.26; 95% CI, 1.82-5.83).4 In 2005, another case-control study nested in the 32,700 Nimes Obstetricians and Haematologists (NOHA) cohort reported an association between FVL and pregnancy loss after 10 weeks (OR, 3.46; 95% CI, 2.53-4.72) but not for losses between 3 and 9 weeks.5 However, although these studies suggested a link between FVL, and perhaps other thrombophilias, and stillbirth, the absolute magnitude of the association was modest. A 3-fold increase of a rare event is still a rare event.

Related Videos
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit:
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit:
Related Content
© 2024 MJH Life Sciences

All rights reserved.